Gene therapy/cell therapy for lysosomal storage disease

Area of Science:

• Biomedical Science
• Genetics
• Molecular Biology

Background:

• Lysosomal storage diseases (LSDs) are genetic disorders impacting cellular waste disposal.
• The Sly mouse serves as an authentic model for human beta-glucuronidase deficiency (Mucopolysaccharidosis type VII).
• Gene and cell therapies are potential treatment modalities for LSDs.

Purpose of the Study:

• To evaluate the efficacy of in vivo and ex vivo gene therapy for lysosomal storage diseases.
• To assess the therapeutic potential of genetically engineered macrophages in a mouse model of MPS VII.

Main Methods:

• In vivo gene therapy involved intravenous administration of a recombinant adenovirus expressing human beta-glucuronidase to Sly mice.
• Ex vivo gene therapy utilized macrophages derived from bone marrow cells, either from normal mice or genetically modified Sly mice.
• Transplantation of normal macrophages and genetically engineered macrophages into Sly mice was performed.

Main Results:

• In vivo gene therapy increased beta-glucuronidase activity in the liver and spleen of Sly mice, with persistent expression and pathological improvement.
• Ex vivo transplantation of normal macrophages transiently increased enzyme activity and improved pathology in Sly mice.
• Genetically engineered macrophages significantly reduced glycosaminoglycan accumulation in Sly mice.

Conclusions:

• Both in vivo and ex vivo gene therapy strategies show therapeutic potential for lysosomal storage diseases.
• Genetically engineered macrophage transplantation represents a promising ex vivo gene therapy approach for LSDs.
• Further investigation into treating central nervous system involvement in LSDs via gene/cell therapy is warranted.